Clinical Trial Detail

NCT ID NCT02971956
Title A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

esophagus adenocarcinoma

esophagus squamous cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.